Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Phase 2

Completed

Conditions: Medulloblastoma With Extensive Nodularity
Medulloblastoma
Nevoid Basal Cell Carcinoma Syndrome
Desmoplastic/Nodular Medulloblastoma

Interventions: Drug: Carboplatin
Other: Cognitive Assessment
Drug: Cyclophosphamide
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Vincristine Sulfate

First Posted Date: 2013-12-23

Last Posted Date: 2023-01-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT02017964

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 170 locations

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 2

Withdrawn

Conditions: Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Childhood Liver Cancer
Hepatoblastoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma

Interventions: Drug: Imetelstat Sodium
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-12-13

Last Posted Date: 2018-08-07

Lead Sponsor: Children's Oncology Group

Registration Number: NCT02011126

Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

Completed

Conditions: Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)

Interventions: Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-06-12

Last Posted Date: 2016-07-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1650

Registration Number: NCT01876303

Locations: 🇺🇸
Children's Oncology Group, Monrovia, California, United States

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Phase 2

Completed

Conditions: Juvenile Myelomonocytic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Other: Pharmacological Study
Drug: Tacrolimus

First Posted Date: 2013-04-05

Last Posted Date: 2018-12-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 30

Registration Number: NCT01824693

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 47 locations

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

Phase 3

Completed

Conditions: Bacterial Infection
Methicillin-Resistant Staphylococcus Aureus Infection
Benign Neoplasm
Myeloid Neoplasm
Recurrent Childhood Acute Myeloid Leukemia
Malignant Neoplasm
Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions: Procedure: Chlorhexidine Gluconate Skin Cleanser
Other: Laboratory Biomarker Analysis
Procedure: Mild Soap Skin Cleanser
Other: Questionnaire Administration

First Posted Date: 2013-03-22

Last Posted Date: 2021-06-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 177

Registration Number: NCT01817075

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 56 locations

Gene Analysis in Studying Susceptibility to Wilms Tumor

Completed

Conditions: Stage II Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor
Recurrent Childhood Kidney Neoplasm
Stage I Kidney Wilms Tumor

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2013-03-11

Last Posted Date: 2016-08-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1

Registration Number: NCT01808079

Locations: 🇺🇸
Childrens Oncology Group, Philadelphia, Pennsylvania, United States

Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma

Completed

Conditions: Osteosarcoma

Interventions: Other: laboratory biomarker analysis

First Posted Date: 2013-03-08

Last Posted Date: 2016-03-08

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 10

Registration Number: NCT01807143

Locations: 🇺🇸
Children's Oncology Group, Monrovia, California, United States

Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

Completed

Conditions: Localized Osteosarcoma
Metastatic Osteosarcoma
Recurrent Osteosarcoma

Interventions: Other: laboratory biomarker analysis

First Posted Date: 2013-03-08

Last Posted Date: 2016-05-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 34

Registration Number: NCT01807052

Locations: 🇺🇸
Children's Oncology Group, Monrovia, California, United States

Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Other: laboratory biomarker analysis

First Posted Date: 2013-03-01

Last Posted Date: 2016-07-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 49

Registration Number: NCT01802125

Locations: 🇺🇸
Children's Oncology Group, Monrovia, California, United States

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 1

Completed

Conditions: Stage 2B Neuroblastoma
Stage 4S Neuroblastoma
Stage 1 Neuroblastoma
Stage 4 Neuroblastoma
Stage 2 Neuroblastoma
Ganglioneuroblastoma
Stage 2A Neuroblastoma
Stage 3 Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mesna
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2013-02-25

Last Posted Date: 2024-07-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 150

Registration Number: NCT01798004

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 120 locations

AI-Powered Research

Premium Access

Children's Oncology Group

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

Gene Analysis in Studying Susceptibility to Wilms Tumor

Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma

Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma